Background Patients with metastatic bladder cancer have very poor prognosis and
predictive biomarkers are urgently needed for early clinical detection and intervention. In this …

Abstract Comparison of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-
TKI) monotherapy or with bevacizumab in real-world non-small cell lung cancer (NSCLC) …

Simple Summary Previous studies of first-generation EGFR-TKI erlotinib and bevacizumab
combination have demonstrated superior treatment efficacy compared to erlotinib …

Background The addition of anti-angiogenesis drugs to epidermal growth factor receptor
(EGFR)–tyrosine kinase inhibitor (TKI) or chemotherapy in patients with EGFR-mutant non …

Purpose The aim of this study was to investigate the efficacy of various epidermal growth
factor receptor (EGFR)–tyrosine kinase inhibitors (TKIs) plus bevacizumab in advanced …

Simple Summary The addition of bevacizumab or ramucirumab to systemic therapy for
EGFR-mutated non-small-cell lung cancer (NSCLC) patients provides survival benefits. No …

Combining epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with an
anti‐vascular endothelial growth factor (VEGF) agent, bevacizumab or ramucirumab, is …

Acquired resistance is unavoidable with the approval of third-generation epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for first-line therapy of advanced non …

Objective Bevacizumab (trade name Avastin®) is a humanized monoclonal antibody (mAb)
that is widely used in the treatment of various cancers. It is one of the most expensive and …

هدف: بواسیزوماب (با نام تجاری آوستین) یک آنتی بادی مونوکلونال (mAb) انسانی شده است که به
طور گسترده ای در درمان سرطان های مختلفی کاربرد دارد. این دارو جزء گرانقیمت ترین و پرفروش …‎